Press Releases
2023
CG Oncology Announces New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pembrolizumab) in BCG-Unresponsive NMIBC
- 85% (n=29/34) of Evaluable Patients Achieved Complete Response at the Initial 3-Month Timepoint from the Phase 2 Clinical Trial - May 1, 2023, 8:00 AM Eastern Daylight Time IRVINE, Calif. (BUSINESSWIRE)--CG Oncology, Inc. announced updated data from the CORE-001...
New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting
April 10, 2023, 8:00 AM Eastern Daylight Time IRVINE, Calif. (BUSINESSWIRE)--CG Oncology, Inc. today announced acceptance of an oral presentation at the American Urological Association (AUA) 2023 Annual Meeting in Chicago, IL from April 28-May 1, 2023. The updated...
2022
CG Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
IRVINE, Calif., December 27, 2022 – CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, today announced that Arthur Kuan, Chief Executive Officer, will present at the 41st Annual J.P....
CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline
– Co-led by ORI Capital, Longitude Capital and Decheng Capital, with participation from RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge Group and Sirona Capital – – Proceeds to accelerate clinical programs across bladder cancer including in...
CG Oncology Presents New Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin
– 88% (n=28/32) of Evaluable Patients Achieved Complete Response at the Initial 3-Month Timepoint from the Phase 2 Clinical Trial of CG0070 in Combination with KEYTRUDA® (pembrolizumab) for NMIBC Unresponsive to BCG – – CG0070 in Combination with KEYTRUDA was Well...
CG Oncology to Present New Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin at SITC 2022 Annual Meeting
IRVINE, Calif., October 24, 2022 – CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, announced acceptance of an oral presentation at the Society for Immunotherapy of Cancer (SITC) Annual...
CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
– 92% (n=22/24) of Evaluable Patients Achieved Complete Response (CR) at the Initial 3-Month Timepoint from the Phase 2 Clinical Trial of CG0070, an Oncolytic Immunotherapy, in Combination with KEYTRUDA® (pembrolizumab) for NMIBC Unresponsive to BCG – – Promising...
CG Oncology Presents Additional Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
– 91% (n=20/22) of Evaluable Patients Achieved Complete Response (CR) at the Initial 3-Month Timepoint – IRVINE, Calif., May 16, 2022 - CG Oncology, Inc., a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for patients with advanced...
2021
CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of CG0070 in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
– Company Receives $10 Million Milestone Payment from Kissei Pharmaceutical Co., Ltd. – IRVINE, Calif., December 20, 2021 – CG Oncology, Inc., a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for patients with advanced cancer,...
CG Oncology Presents Preliminary Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
– 100% of Patients Evaluable for Efficacy (N=9) Achieved Complete Response (CR) at the Initial 3-Month Timepoint – – For Patients That Reached Additional Timepoints, 100% (N=6) Have Also Maintained a CR Through 6 Months and 100% (N=3) at the 9-Month Assessment – –...
CG Oncology to Present Two Programs at The Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
– Oral Presentation Providing Update on the Phase 2 Clinical Trial of CG0070, an Oncolytic Immunotherapy, in Combination with KEYTRUDA® (pembrolizumab) for NMIBC Unresponsive to BCG – – Poster Presentation Providing Overview of the Global Phase 3 Clinical Trial of...
CG Oncology and Roche to Collaborate on Clinical Trial of Oncolytic Immunotherapy CG0070 as Part of Novel Combination for Various Solid Tumor Indications
IRVINE, Calif., September 22, 2021 – CG Oncology, Inc. announced today that it has entered into a clinical trial collaboration agreement to evaluate the combination of CG Oncology’s investigational oncolytic immunotherapy CG0070, with Roche’s atezolizumab, an...
CG Oncology Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Oncolytic Immunotherapy CG0070 in Combination with OPDIVO® (nivolumab) in Metastatic Urothelial Cancer
IRVINE, Calif., September 9, 2021 – CG Oncology, Inc. today announced a clinical trial collaboration to evaluate the safety and efficacy of CG0070, an oncolytic immunotherapy, in combination with OPDIVO® (nivolumab), Bristol Myers Squibb’s anti-PD-1 therapy, for the...
2020
CG Oncology Closes $47 Million Series D Financing
IRVINE, Calif., December 10, 2020 – CG Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, today announced the closing of a $47 million Series D preferred stock financing led by new investor Kissei...
CG Oncology Announces First Patient Dosed in Phase 2 Clinical Trial of CG0070, an Oncolytic Immunotherapy, in Combination with KEYTRUDA® (pembrolizumab) for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
IRVINE, Calif., December 9, 2020 – CG Oncology, Inc., a clinical-stage immuno-oncology company, today announced the first patient has been dosed in CORE1, a Phase 2 clinical trial of CG0070 in combination with KEYTRUDA® (pembrolizumab), for the treatment of patients...
CG Oncology Announces First Patient Dosed in Phase 1b Study of Oncolytic Immunotherapy CG0070 in Combination with OPDIVO® (nivolumab) in Muscle-Invasive Bladder Cancer
– Investigator-Initiated Study Will Be Conducted at Moffitt Cancer Center and Enroll Up to 30 Patients with Muscle-Invasive Bladder Cancer – IRVINE, Calif., November 12, 2020 – CG Oncology, Inc. announced today that the first patient has been treated in an...
CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical Co., Ltd. for CG0070 in Japan and Other Asian Countries
– Kissei Gains Regional License to CG0070 for Japan, South Korea, Taiwan and Other Asian Countries With the Exception of China – – Deal Valued at Up to $140 Million Plus Royalties, Including a $10 Million Licensing Fee and $30 Million Equity Investment – IRVINE,...
2019-2014
$22 Million Series C Financing
– Investment to Advance Clinical Development of Oncolytic Immunotherapies in Bladder Cancer and other Solid Tumors – SANTA ANA, Calif., March 18, 2019 – Cold Genesys, Inc., a clinical-stage biopharmaceutical company focused on the development of novel immunotherapies,...
Clinical Trial Collaboration to Evaluate the Combination of CG0070 and KEYTRUDA® (pembrolizumab) in Bladder Cancer
SANTA ANA, Calif., November 28, 2018 – Cold Genesys, Inc. today announced that it has entered into a clinical collaboration with Merck (known as MSD outside the United States and Canada) to evaluate the combination of Cold Genesys’ lead oncolytic immunotherapy...
Clinical Results at American Urological Association (AUA) Annual Meeting 2017
SANTA ANA, Calif., May 15, 2017 – Cold Genesys Incorporated (“Cold Genesys”), a late-stage immuno-oncology company, today reported interim clinical data from the Phase II trial (BOND2) evaluating Cold Genesys' investigational oncolytic virotherapy, CG0070, in patients...
FDA Acceptance of a Phase I/II Clinical Trial Using CG0070 Plus an Anti-CTLA-4 Checkpoint Inhibitor as a Neo-Adjuvant Immunotherapy for Muscle Invasive Bladder Cancer
SANTA ANA, Calif., October 19, 2015 – Cold Genesys, Inc., a late-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) accepted a Phase I/II Clinical Trial (NAOMI) using CG0070 plus an anti-CTLA-4 checkpoint inhibitor as a...
Series B Investment for Pivotal and Combo Immunotherapy Trials
– Ally Bridge and WI Harper Co-lead US$10 million Series B Financing – SANTA ANA, Calif., August 05, 2015 – Cold Genesys Inc., a clinical-stage oncolytic immunotherapy company, today announced the successful completion of a Series B financing co-led by Ally Bridge...
$13.57 Million in a Series A Round of Financing to Accelerate Its Ongoing Phase II/III Clinical Trial for Bladder Cancer
NEWPORT BEACH, Calif., July 30, 2014 – Cold Genesys, Inc. (“CGI”), a clinical-stage biopharmaceutical company developing oncolytic immunotherapies for cancer, announced today that it has secured Series A financing of $13.57 million from Ally Bridge Group. CGI will...
